Integrated Assessment of Cervicocerebral Vessels to Improve the Brain Injury for CAGB Patients (IACV Study)
Launched by CHINA NATIONAL CENTER FOR CARDIOVASCULAR DISEASES · Feb 17, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The IACV Study is a clinical trial aimed at improving the care of patients with coronary artery disease who are at high risk for strokes and need surgery called coronary artery bypass graft (CABG). The trial will compare two groups of patients: one group will receive standard care, which includes basic imaging tests like a CT scan of the head and ultrasound of the carotid arteries, while the other group will have a more thorough assessment involving multiple specialists. This second group will undergo additional tests to evaluate the health of their brain and blood vessels, and their treatment plans will be developed collaboratively by a team of doctors from different specialties.
To participate in this study, individuals must be at least 18 years old and have a history of stroke or related symptoms, along with specific high-risk imaging results. The trial is currently recruiting patients, so if someone meets these criteria, they could take part. Participants can expect to receive either the standard care or the more comprehensive assessment and treatment approach, and researchers will analyze the outcomes to see if the integrated assessment helps reduce the risk of brain injury during surgery. It’s important to know that patients over 80 years old, those with certain blood vessel conditions, or anyone unwilling to consent or follow up will not be eligible for this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who require CABG surgery; Age ≥18 years with a history of stroke or transient ischemic attack; Combined with typical symptoms of stroke; Previous imaging findings suggest a high risk of stroke
- Exclusion Criteria:
- • \< 18 years old; \> 80 years old; Combined with congenital cerebrovascular malformation; Emergency operation; Reluctant to sign an informed consent form; Reluctant to follow up
About China National Center For Cardiovascular Diseases
The China National Center for Cardiovascular Diseases (NCCD) is a leading research and clinical trial sponsor dedicated to advancing cardiovascular health in China and globally. As a prominent institution, NCCD focuses on innovative research, clinical management, and education in cardiovascular medicine. The center plays a crucial role in conducting rigorous clinical trials aimed at developing new therapies and improving patient outcomes for cardiovascular diseases. Through collaboration with national and international partners, NCCD is committed to enhancing the understanding of cardiovascular conditions and translating research findings into practical applications for improved healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Fei Xu, MD
Principal Investigator
Fuwai Hospital; National Cardiovascular Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported